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ABSTRACT
Novel therapeutics targeting neutrophilic inflammation
are a major unmet clinical need in acute and chronic in-
flammation. The timely induction of neutrophil apoptosis
is critical for inflammation resolution, and it is thought that
acceleration of apoptosis may facilitate resolution at in-
flammatory sites. We previously demonstrated that a
death receptor ligand, TRAIL, accelerates neutrophil apo-
ptosis in vitro. We examined the role of TRAIL in neutro-
phil-dominant inflammation in WT and TRAIL-deficient
mice. TRAIL deficiency did not alter constitutive neutrophil
apoptosis, whereas exogenous TRAIL accelerated apo-
ptosis of murine peripheral blood neutrophils. We com-
pared TRAIL-deficient and WT mice in two independent
models of neutrophilic inflammation: bacterial LPS-in-
duced acute lung injury and zymosan-induced peritonitis.
In both models, TRAIL-deficient mice had an enhanced
inflammatory response with increased neutrophil num-
bers and reduced neutrophil apoptosis. Correction of
TRAIL deficiency and supraphysiological TRAIL signaling
using exogenous protein enhanced neutrophil apoptosis
and reduced neutrophil numbers in both inflammatory
models with no evidence of effects on other cell types.
These data indicate the potential therapeutic benefit of
TRAIL in neutrophilic inflammation. J. Leukoc. Biol. 90:
855–865; 2011.
Introduction
The resolution of acute inflammation requires recruited
neutrophils to undergo programmed cell death by apoptosis
in a timely manner after completion of effective host de-
fense functions. This response limits the potential for by-
stander tissue damage. There is evidence that the onset of
apoptosis is tightly coupled to inflammation resolution
[1, 2]. Conversely, neutrophil lifespan is prolonged in tis-
sues [3], and neutrophil apoptosis may be delayed at sites
of inflammation by a wide range of proinflammatory stimuli
[4]. Recent data emphasize the potential of pharmacologi-
cal strategies to “drive” neutrophil apoptosis in vivo
and thus, to aid clearance of the inflammatory infiltrate [2].
The molecular mechanisms governing the onset of neutro-
phil apoptosis are surprisingly ill-defined. Few stimuli inducing
physiological neutrophil apoptosis have been described. More-
over, many factors modulate other neutrophil functions in ad-
dition to apoptosis, emphasizing the importance of elucidating
mechanisms that are selective for the control of apoptosis. The
death receptor FasL induces neutrophil apoptosis [5, 6] with
evidence for a role in acute lung injury [7] but is also a stimu-
lus to neutrophil recruitment [6]. Another death receptor li-
gand, TNF-, has a modest, proapoptotic effect, which is later
opposed by its downstream, prosurvival effects, mediated via
NF-B activation [8], resulting in a net delay of neutrophil
apoptosis [9]. We have previously shown that the death recep-
tor ligand TRAIL induces neutrophil apoptosis without NF-B
activation in vitro and without the chemoattractant effects of
FasL [10]. More recently, TRAIL has been implicated in elimi-
nating senescent, circulating neutrophils [11].
TRAIL is a type II membrane protein principally expressed by
leukocyte populations [12]. In humans, TRAIL interacts with four
membrane receptors belonging to the TNFR family. TRAIL-R1
and TRAIL-R2 have cytoplasmic death domains and can activate
caspases and NF-B [13]. The decoy receptors TRAIL-R3
and TRAIL-R4 have truncated death domains and do not activate
caspases but may activate NF-B [13]. A soluble decoy receptor for
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TRAIL, osteoprotegerin, is also described. Mice have a single TRAIL
death receptor, which shares 79% sequence homology with human
TRAIL-R2 [14], together with two decoy receptors.
TRAIL-deficient mice have demonstrated an increased adaptive
immune response in mouse models of autoimmune arthritis [15]
and encephalomyelitis [16]. TRAIL deficiency has been associ-
ated with increased neutrophil survival in a murine model of lis-
teriosis [17] and in a pneumococcal meningitis model [18], in
the latter case, with reduced cerebral inflammation and im-
proved outcomes following rTRAIL treatment. These studies sug-
gest TRAIL-induced apoptosis may be a key mechanism regulat-
ing the neutrophilic response to bacterial infection.
To determine the potential of TRAIL signaling to modulate neu-
trophil apoptosis during neutrophil-dominant inflammation, we
have examined its role in two well-characterized models: LPS-medi-
ated acute lung injury and zymosan-induced peritonitis. We show
mice deficient in TRAIL have no defect of neutrophil recruitment
but have delayed neutrophil apoptosis and delayed inflammation
resolution. Importantly, administration of exogenous TRAIL not
only restores a WT phenotype to TRAIL-deficient mice but also ac-
celerates inflammation resolution in WT mice.
MATERIALS AND METHODS
Animals
TRAIL-deficient mice on a C57/BL6 background were a kind gift from Am-
gen (Seattle, WA, USA) via Dr. Mark Smyth (University of Melbourne, Austra-
lia) and have been described previously [19]. TRAIL-deficient mice and WT
controls (8–12 weeks) were anesthetized with an i.p injection of ketamine (Ke-
taset, 100 mg/kg; Willows Francis Veterinary, Crawley, UK), xylazine hydro-
chloride (10 mg/kg; Bayer, Suffolk, UK), and atropine (0.02 mg/kg; Phoenix
Pharmaceuticals, Burlingame, CA, USA). All procedures were approved by the
University of Sheffield Ethics Committee (UK) and were performed in accor-
dance with the Home Office Animal (Scientific Procedures) Act 1986.
Materials
Goat anti-rat IgG microbeads were obtained from Miltenyl Biotec (Bisley,
UK). Rat anti-mouse antibodies to CD2 (Rm2-5), CD5 (53-7.3), and
CD45R (RA3-6B2) were obtained from BD PharMingen (Oxford, UK). Rat
anti-mouse F4/80 antigen (Clone A3-1) and CD-115 were purchased from
Serotec (Kidlington, UK). LPS from Escherichia coli serotype 10 and zymo-
san were obtained from Sigma-Aldrich (Poole, UK). Murine rTRAIL was
purchased from Biomol International (UK).
Preparation of peripheral blood neutrophils
This method has been described previously [20]. Briefly, 1 ml blood was
collected via cardiac puncture from anesthetized mice using a heparinized
syringe and was transferred into dextran T500 (Amersham Pharmacia Bio-
tech, Buckinghamshire, UK), 1.25% w/v in saline, to a final volume of 10
ml. Following erythrocyte sedimentation, leukocyte-containing supernatants
from three mice were pooled and washed in PBS buffer with 0.5% BSA,
pH 7.4. After cytocentrifugation of an aliquot to obtain differential cell
counts, leukocytes were incubated with anti-CD2 (1.5 g/106 lymphocytes),
-CD5 (2 g/106 lymphocytes), -CD45R (10 g/106 lymphocytes), -F4/80 (2
g/106 monocytes), and -CD115 (15 g/106 lymphocytes) prior to negative
selection of neutrophils using a cooled LD column attached to a MACS
magnet (Miltenyl Biotec). The final yield was 1  106 neutrophils for
each group of mice. Neutrophil purity was assessed by differential counts of
cytocentrifuge preparations, and samples of 90% purity were obtained
for subsequent experiments. Neutrophil viability was assessed by trypan
blue staining and was always 98.5%.
Neutrophil culture
Neutrophils were cultured at 1.0  106/ml in RPMI 1640 (Sigma-Aldrich)
with 10% FCS with added glutamine, penicillin, and streptomycin (100
U/L), all from Life Technologies (Paisley, UK). Aliquots (100 l) of cells
were cultured with and without 100 ng/ml rTRAIL in nontissue culture-
treated Falcon “Flexiwell” plates (BD PharMingen) at 37°C in a 5% CO2
atmosphere. Cells were harvested from culture at 6, 12, and 18 h.
Assessment of neutrophil viability and apoptosis
At the time-points described, cytocentrifuge preparations were made and
the proportion of apoptotic neutrophils determined by counting duplicate
cytospins (300 cells/slide), stained by Diff-Quick (Merck, Dorset, UK). In
keeping with previous work [1], we found that the morphological features
of apoptotic and nonapoptotic murine neutrophils could be clearly distin-
guished by light microscopy (see Fig. 1A). In addition, membrane integrity
was assessed at all time-points by exclusion of the vital dye trypan blue,
and necrosis, defined as trypan blue-positive cells without morphological
Figure 1. Effects of TRAIL on apoptosis of murine peripheral blood neutrophils. (A) Cytocentrifuge preparation of purified peripheral blood
neutrophils from TRAIL-deficient mice shows apoptotic neutrophils (arrows) readily distinguishable from neutrophils of nonapoptotic morphol-
ogy. (B) Neutrophils were purified from peripheral blood and sampled after 6, 12, and 18 h in culture. Apoptosis was assessed by cytospin mor-
phology of neutrophils from control (open bars) and TRAIL-deficient (filled bars) and plotted against time (h); n4. At t  0 h, apoptosis was
1.0%. There were no statistically significant differences between WT and TRAIL-deficient in constitutive neutrophil apoptosis. (C) Addition of
rTRAIL accelerated apoptosis of WT neutrophils. Freshly isolated peripheral blood neutrophils were cultured with or without TRAIL (100 ng/ml).
Mean  sem of the percentage of apoptotic cells is shown for control (open bars) and TRAIL-treated cells (filled bars); n  4. In both popula-
tions at both time-points, TRAIL treatment caused a significant increase in levels of neutrophil apoptosis.
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features of apoptosis, was 5% unless otherwise stated. Apoptosis was also
assessed by flow cytometry, detecting externalization of phosphatidylserine
using Annexin V (BD PharMingen) and costaining with To-Pro 3 (Molecu-
lar Probes, Leiden, The Netherlands) to distinguish late-apoptotic or ne-
crotic cells by failure of the latter to exclude this vital dye [21]. Both fluo-
rescent dyes were used according to the manufacturer’s instructions. Neu-
trophils were identified by staining with FITC-1A8 (BD PharMingen) [21].
Cells were analyzed on a dual-laser FACSCalibur flow cytometer (BD
PharMingen) and a minimum of 10,000 events recorded and analyzed us-
ing CellQuest software (BD PharMingen).
Model of LPS-mediated acute lung injury
The model of i.t. instillation of LPS has been described in detail previously
[22]. A 24-gauge catheter (Jelco; Johnson and Johnson Medical, Ascot, UK)
was inserted into the trachea of anesthetized mice and LPS (0.3 g), or
Figure 2. Inflammatory cell numbers and apoptosis following i.t. administration of LPS in WT and TRAIL-deficient mice. Cell counts were ob-
tained from cytocentrifuge preparations and hemocytometer counts of BALF lavaged from the lungs at time-points up to 144 h; n  10 animals
in each group. In all panels, WT mice are depicted as a solid line and TRAIL-deficient mice as a dashed line. (A) Total leukocyte counts. At 48 h,
there were significantly more leukocytes in the TRAIL-deficient when compared with WT BAL. (B) Total neutrophil counts. At 48 h, there were
significantly more neutrophils in the TRAIL-deficient when compared with WT BAL. (C) The percentage of neutrophils in TRAIL-deficient mice
was significantly increased after LPS instillation when compared with WT mice. (D) The percentage of macrophages rose in WT and TRAIL-defi-
cient mice over time as inflammation resolved, and TRAIL-deficient mice had a significantly lower percentage. (E) The percentage of BALF neu-
trophils with morphological appearances of apoptosis was assessed. The percentage of apoptotic neutrophils increased in both populations, but at
48, 72, and 96 h, there was a significantly lower proportion of apoptotic neutrophils in the TRAIL-deficient mice. Neutrophil apoptosis was also
assessed by flow cytometry. (F) The percentage of apoptotic neutrophils (IA8/Annexin V) was significantly reduced in TRAIL-deficient mice at
48 h compared with WT mice (P0.05). Histologic sections of mice 24 h post-LPS treatment were TUNEL-stained for detection of apoptotic
events. (G) Numbers of TUNEL-positive (ve) cells were significantly higher in WT (H) than in TRAIL-deficient mice (I). HPF, per high power
field.
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PBS as a control was instilled into the lungs using a pipette gel-loading tip
and then flushed through the catheter with air. At the relevant time-points,
experiments were terminated by giving the mice an overdose of sodium
pentabarbitone.
For experiments where rTRAIL was administered i.t., the protocol was
modified to avoid repeat cannulation of the trachea. LPS (3 mg) was deliv-
ered by nebulization at t  0 and then at t  24 h rTRAIL (1 mg/kg), was
given by i.t. cannulation as above.
Model of zymosan-mediated acute peritonitis
Peritoneal inflammation was induced as described previously [23]. Zymo-
san A was prepared (2 mg/ml) in sterile, 0.9% normal saline, and 0.5 ml
was injected i.p. (t0). A subgroup of mice was then injected with 100 g
rTRAIL at 6 h. At 24 h and 48 h, the animals were killed and the perito-
neal cavity lavaged with 2 ml saline. Hemocytometer counts were per-
formed and cytospin preparations made for differential cell counts and as-
sessment of apoptosis. The supernatant was removed and stored at –70°C.
BAL
BAL was performed using five 0.8 ml aliquots of 10 U/ml ice-cold heparin-
ized saline (Leo Laboratories, Ireland), which were then pooled [21]. A
total of 10 l BAL was diluted in 90 l 3% acetic acid for a hemocytometer
total cell count. Cytospin preparations were made from each BAL sample
(100 l), stained with Diff-Quick, and assessed by blinded reviewers. Differ-
ential cell counts, including the proportion of neutrophils that was apopto-
tic, were then calculated using the fractions for each leukocyte population
estimated by analysis of cytospin preparations. The remainder of the BALF
was centrifuged (300 g for 6 min), supernatant was stored at –70°C,
and the cell pellet was resuspended for flow cytometry.
Cytokine and IgM measurements in BAL
Cytokine/chemokine concentrations were measured by CBA flex sets and a
FACSArray bioanalyzer (BD Biosciences, San Jose, CA, USA), in accordance
with the manufacturer's protocols. As a marker of pulmonary vascular leak
and thus, of lung injury [24], IgM concentration in BAL was determined
by ELISA (Bethyl Laboratories, Montgomery, TX, USA), in accordance
with the manufacturer's protocol.
Immunohistochemistry and TUNEL staining
Unlavaged lungs were fixed via the trachea with 10% buffered formalin at
20 cm H2O, processed, and embedded in paraffin wax blocks. Lung sam-
ples were serially sectioned at 5 m and processed using 0.6 mol/L sodium
citrate buffer (pH 6) antigen retrieval where required, as described previ-
ously [25]. Serial sections were stained with mouse mAb to TRAIL (Vector
Laboratories, Peterborough, UK), as described previously [26], incubated
for 1 h, labeled using a streptavidin avidin biotin complex peroxidase tech-
nique (Vector Laboratories), and visualized with 3,3-diaminobenzidine
(DakoCytomation, Denmark). Negative controls involved incubation with
isotype antibody/secondary antibody alone. TUNEL was performed using
an ApopTag peroxidase in situ apoptosis detection kit (Chemicon Interna-
tional, Temecula, CA, USA), as per the manufacturer’s instructions.
Statistical analysis
Results are expressed as mean  se and were analyzed for statistical vari-
ance using a one- or two-way ANOVA as appropriate, followed by a Bonfer-
roni’s post-test for multiple comparisons. Results were considered signifi-
cant if P  0.05. In all figures, *P  0.05; **P  0.01; and ***P  0.001.
RESULTS
Constitutive apoptosis of peripheral blood
neutrophils from TRAIL-deficient mice
We confirmed that there were no differences in total leukocyte
numbers and numbers of circulating neutrophils between
TRAIL-deficient and WT mice (data not shown), as described
previously [19]. In freshly isolated peripheral blood neutro-
phils, there was no difference in numbers of apoptotic neutro-
phils: percentage of WT neutrophils showing morphological
features of apoptosis was 0.53  0.29% (meansem) versus
0.40  0.20% for TRAIL-deficient mice; n  3. When cultured
in vitro, neutrophils underwent constitutive apoptosis (Fig.
1A), with no significant difference in the percentage of apo-
ptotic cells between WT and TRAIL-deficient neutrophils at 6,
12, or 18 h (Fig. 1B).
TRAIL induces neutrophil apoptosis in vitro
Having previously shown that TRAIL induces apoptosis of hu-
man neutrophils [10], we evaluated the effect of exogenous
TRAIL on murine neutrophils. WT neutrophils were isolated
and cultured with rTRAIL (100 ng/ml) for 6 h and 18 h.
rTRAIL treatment resulted in an increase in neutrophil apo-
ptosis at 6 h and 18 h in WT and TRAIL-deficient neutrophils
(Fig. 1C).
LPS-mediated neutrophilic inflammation is enhanced
and neutrophil apoptosis decreased in TRAIL-
deficient mice
As described previously [1], i.t. LPS induced rapid neutrophil
migration into the lungs of challenged mice, as assessed by
TABLE 1. Levels of Chemokines and Cytokines in BALF
24 h 48 h
C57BL6 TRAIL–/– P value C57BL6 TRAIL–/– P value
TNF- pg/ml 262 (104–751) 244 (175–398) NS 80.7 (7–126) 77.8 (9.2–154) NS
KC (CXCL1) pg/ml 8.2 (7.9–9.7) 7.57 (4.46–11.1) NS 3.44 (1.7–4.26) 4.0 (3.7–4.96) NS
IL-1 pg/ml 21.8 (12.3–24) 31.2 (24.1–40.6) 0.05 17.9 (9.1–31.7) 28.8 (12.1–63.5) NS
IL-1 pg/ml 10.3 (9.9–11.9) 11.4 (10.2–14.3) NS 9.97 (9.97–13.6) 9.97 (9.97–19.8) NS
MIP-1 (CCL3) pg/ml 34.6 (19.7–45) 47.5 (42.1–49.5) NS 27.2 (21.2–40.3) 27.9 (10.4–70.3) NS
MIP-1 (CCL4L1) pg/ml 57.5 (32–61.5) 97.5 (89.3–115) 0.05 63.60 (10.3–72.3) 63.6 (10.6–172) NS
MIP-2 g/ml 44.2 (15.4–87.3) 48.5 (32.2–75.9) NS 15 (3.8–36.2) 10.6 (4.1–21) NS
A range of cytokines and chemokines was measured at 24 h and 48 h following LPS instillation. All values are shown as median(range) and rep-
resent the values obtained from five independent experiments (n  5). TRAIL–/–, TRAIL-deficient.
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BAL at time-points up to 144 h following instillation. Total cell
counts and percent neutrophil counts were increased in WT
and TRAIL-deficient mice by 24 h after LPS instillation when
compared with mice instilled with PBS alone. The numbers of
neutrophils in BALF from control mice were 0.1  105 neu-
trophils at 24 h and at all subsequent time-points in WT and
TRAIL-deficient strains (data not shown). There was an en-
hanced inflammatory response in TRAIL-deficient compared
with WT mice, apparent from 48 h after LPS instillation, with
significantly increased total cell counts and total and percent
neutrophil counts (Fig. 2, A–C). There were small reciprocal
changes in BAL percent macrophages (Fig. 2D), but total
numbers of macrophages were unchanged (data not shown).
Very few lymphocytes were present, and no significant differ-
ence in total lymphocyte counts was observed between WT
and TRAIL-deficient mice (data not shown). Apoptosis of BAL
neutrophils was assessed using morphologic criteria as de-
scribed previously [1]. From the 48-h time-point onward, there
was a significantly lower proportion of apoptotic neutrophils in
the TRAIL-deficient compared with WT mice (Fig. 2E). These
findings were confirmed at the 48-h time-point by identifica-
tion of Annexin-V-positive cells within the IA8-positive neutro-
phil population by flow cytometry (Fig. 2F), but this method
was not reliable at later time-points as a result of reduced cell
numbers. Apoptosis of tissue cells was quantified using TUNEL
staining (Fig. 2, G–I) and appeared largely confined to the
influxing inflammatory cells, which were predominantly neu-
trophils.
Cytokine and chemokine levels in BAL
To investigate whether TRAIL might have an effect on pulmo-
nary neutrophilia other than through reduced neutrophil apo-
ptosis, chemokines and cytokines involved in neutrophil re-
cruitment were measured in BAL (Table 1). There were no
significant differences in levels of KC at any of the time-points
studied. MIP-2 was markedly raised at 24 h, in keeping with
previous studies [27], but levels did not differ between WT
and TRAIL-deficient mice. IL-17 was not detected at either
time-point in WT or TRAIL-deficient mice (data not shown).
These data, combined with the observation that there was no
difference in neutrophil numbers until 48 h after LPS instilla-
tion, suggested that neutrophil persistence in the TRAIL-defi-
cient animals was unlikely to be a result of excessive, ongoing
recruitment. No significant differences in TNF-, IL-1, or
MIP-1 levels were observed at any time-point. MIP-1
and IL-1 levels were significantly higher in TRAIL-deficient
mice at 24 h, but although statistically significant, the differ-
ences were not large in comparison with previous studies
[1, 28].
IgM levels in BAL were increased in TRAIL-deficient
mice following LPS instillation
An increase in neutrophil numbers can be associated with in-
creased vascular permeability and lung injury in murine mod-
els of pulmonary inflammation [24, 28]. As described previ-
ously [24], we measured IgM levels in BAL between the two
murine strains and found significantly increased IgM in BAL
of TRAIL-deficient mice at 48 h and 72 h following LPS instil-
lation, the time-points at which we also saw significant differ-
ences in neutrophil numbers in BAL (Fig. 3).
TRAIL immunolocalization after LPS-induced lung
injury/TRAIL expression
Immunohistochemical examination of TRAIL expression in
the lung was performed at key time-points in WT mice. In WT
animals receiving i.t. saline, TRAIL staining was observed only
in small pulmonary arteries (Fig. 4A). After LPS administra-
tion to WT mice, immunostaining was seen predominantly in
bronchial epithelial cells but with occasional staining of alveo-
Figure 3 . IgM levels in BALF following i.t. administration of LPS in
WT and TRAIL-deficient mice. Total IgM levels measured by ELISA in
BAL at 48 h and 72 h were significantly higher in TRAIL-deficient
(filled bars) compared with WT mice (open bars; P0.05; n5).
Figure 4. TRAIL expression following i.t.
LPS. Lung sections 48 h after i.t. instilla-
tion of saline (control) or LPS were im-
munostained for TRAIL. (A) Lung sec-
tion demonstrating lack of positive TRAIL
staining in the airways of a WT mouse
following saline administration. TRAIL
staining is identified only where associ-
ated with small pulmonary arteries.
(B) Lung section demonstrating TRAIL
expression principally in the bronchial
epithelium following LPS challenge of WT mice, with occasional staining of alveolar macrophages. (C) Lung section demonstrating absence of
specific TRAIL staining in a TRAIL-deficient lung (negative control). These sections are representative of multiple sections cut in a minimum of
three experiments. All images, 200 original magnification; scale bar represents 100 m.
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lar macrophages (Fig. 4B). Staining of sections from TRAIL-
deficient mice was negative (Fig. 4C). Importantly, in TUNEL
staining of lung sections, there was no evidence of excess epi-
thelial cell death, either alveolar or in the airways (Fig. 2,
G–H), following LPS treatment in WT compared with TRAIL-
deficient mice, despite enhanced TRAIL immunostaining in
these cells.
Zymosan-mediated peritoneal inflammation is
enhanced in TRAIL-deficient mice
As described previously [23], i.p. zymosan induced neutrophil
migration into the peritoneum of challenged mice, assessed by
peritoneal lavage at time-points up to 48 h following instilla-
tion. Total neutrophil counts were increased in WT
and TRAIL-deficient mice when compared with mice instilled
with PBS alone (Fig. 5A). No significant differences between
the two strains in macrophage or lymphocyte numbers were
observed (data not shown). The proportion of the neutrophil
lavage population that had the microscopic appearances of
apoptosis at 24 h and 48 h was significantly lower in the
TRAIL-deficient mice (Fig. 5B).
Administration of rTRAIL induces neutrophil
apoptosis and reduces neutrophil numbers in
pulmonary and peritoneal inflammatory models
in vivo
To explore the effects of exogenous TRAIL on neutrophilic
inflammation and apoptosis in vivo, we first established a
model of acute pulmonary inflammation induced by nebulized
LPS. This required a larger dose of LPS (3 mg), compared
with 0.3 g by i.t. administration, and slightly higher levels of
neutrophilia were induced, together with the expected differ-
ence in neutrophil counts at 48 h between WT and TRAIL-
deficient mice (Fig. 6, A and B). Neutrophilic inflammation
was established over 24 h and then rTRAIL delivered i.t., seek-
ing evidence of accelerated inflammation resolution at 48 h
after the initial challenge. TRAIL treatment significantly re-
duced neutrophil numbers (total cell count and percent) in
TRAIL-deficient and WT mice (Fig. 6, A and B). There was no
significant effect on macrophage numbers (data not shown).
There was an increase in the proportion of apoptotic neutro-
phils detected in BAL following TRAIL treatment (Fig. 6C).
Moreover, TUNEL staining of WT lung sections revealed an
increase in the numbers of apoptotic cells detected following
TRAIL treatment (Fig. 6, D–F). Again, these apoptotic events
appeared largely confined to the inflammatory infiltrate, with
no evidence that TRAIL treatment resulted in significant epi-
thelial cell death. We also determined whether TRAIL treat-
ment induced a neutrophil chemokine response. KC and IL-17
were undetectable at this time-point in the presence or ab-
sence of TRAIL treatment, whereas MIP-2 levels were raised as
before but not significantly different (data not shown).
In the peritonitis model, rTRAIL was injected 6 h following
i.p. administration of zymosan and neutrophil counts and lev-
els of apoptosis assessed at 24 h. TRAIL treatment again re-
sulted in significantly reduced neutrophil numbers in TRAIL-
deficient and WT mice (Fig. 7, A and B), with increased neu-
trophil apoptosis, as assessed by morphologic criteria (Fig.
7C), indicating efficacy of TRAIL treatment in pulmonary
and systemic inflammation.
DISCUSSION
In these studies, we show that neutrophils deficient in the
death receptor ligand TRAIL have normal constitutive apopto-
sis. However, in two independent inflammatory models, ani-
mals deficient in TRAIL show delayed neutrophil apoptosis
and increased neutrophilic inflammation. In both models, ad-
ministration of exogenous TRAIL restored the WT phenotype
in TRAIL-deficient mice and importantly, accelerated neutro-
phil apoptosis and reduced neutrophil numbers in WT mice
(Fig. 8). In contrast to the effects of other death receptor li-
gands that cause death or inflammatory responses in multiple
cell populations, the effect of TRAIL appeared to be restricted
to the selective induction of neutrophil apoptosis.
Although the role of death receptor ligands such as FasL
and TNF- in accelerating neutrophil apoptosis is well recog-
Figure 5. Neutrophil counts and apoptosis in peritoneal lavage fluid
following i.p. administration of zymosan in WT and TRAIL-deficient
mice. (A) Total neutrophil counts were obtained from cytocentrifuge
preparations of lavage fluid from the peritoneum at 24 h and 48 h
(n5 experiments), multiplying the differential count by the total leu-
kocyte number obtained from hemocytometer counts. (B) The per-
centage of lavage neutrophils with morphological appearances of apo-
ptosis was calculated. At 24 h and 48 h, the percentage of apoptotic
neutrophils was increased in both populations, but there was a signifi-
cantly lower proportion of apoptotic neutrophils in the TRAIL-defi-
cient (filled bars) compared with WT (open bars) mice.
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nized, each also has significant proinflammatory effects, with
FasL inducing neutrophil chemotaxis [29] and TNF- having
an antiapoptotic effect mediated via NF-B [8, 9]. We previ-
ously showed that TRAIL had neither of these effects in hu-
man neutrophils in vitro and postulated that TRAIL treatment
might regulate neutrophil apoptosis in vivo [10]. The TRAIL
system has since been implicated in the elimination of senes-
cent circulating neutrophils [11], suggesting a role in physio-
logical regulation of neutrophil lifespan. Further interest in
TRAIL arose, as the majority of primary cell types, although
not all, is resistant to TRAIL, in part, as a result of expression
of cell surface decoy receptors TRAIL-R3 and -R4, reducing
the likelihood of unwanted cytotoxicity in other cell types with
TRAIL treatment in vivo [12]. In contrast, FasL induces apo-
ptosis of bronchial epithelial cells [30], and pulmonary overex-
pression of TNF- induces chronic pulmonary inflammation
and fibrosis [31].
In agreement with earlier studies [18], we found no differ-
ence in neutrophil numbers in the circulation of WT
and TRAIL-deficient mice. When cultured in vitro, there was
no difference in constitutive neutrophil apoptosis between WT
and TRAIL-deficient cells, and both cell types showed an
equivalent apoptotic response to exogenous TRAIL. Examina-
tion of an experimental model of LPS-induced lung inflamma-
tion revealed an increase in the number of neutrophils pres-
ent in the lung in response to LPS, which peaked at 48 h
and resolved thereafter. Multiple studies of LPS-induced acute
lung inflammation have confirmed the transient nature of the
inflammatory response and that modification of individual fac-
tors provides a transient delay rather than complete cessation
of resolution [32, 33]. The total number of neutrophils pres-
ent in the lavage in the WT mice was in keeping with previous
data published by our group and others [1, 34]. There were
clear differences in neutrophil numbers at 24 and 48 h post-
LPS instillation between WT and TRAIL-deficient mice, but by
72 h, total neutrophil numbers were not significantly different,
although in TRAIL-deficient mice, neutrophils remained a
higher proportion of the inflammatory exudate (Fig. 2C),
and fewer of them were apoptotic, as assessed by annexin
V/To-Pro 3 staining, than in the WT (Fig. 2E). Murine models
involving manipulation of neutrophil apoptosis, as we have
described previously [1, 35], show prolonged inflammation
that then resolves, rather than an indefinite failure of resolu-
tion, consistent with what we now demonstrate in the TRAIL-
deficient mice. This convergence between WT and TRAIL-defi-
cient mice at later time-points could also reflect reduced neu-
trophil recruitment in the TRAIL-deficient mice. The
recruitment of neutrophils to the lung cannot be measured
directly in murine models. There were no significant differ-
ences, however, between the murine strains in levels of cyto-
kines typically associated with neutrophil recruitment (KC,
MIP-2, IL-17) or with NF-B activation (KC, MIP-2) [36]. In
other organs, such as the inflamed joint, reverse endothelial
migration of neutrophils has been described [37], but to our
knowledge, retrograde movement of neutrophils back across
the pulmonary epithelium has not been described. Other pro-
resolution molecules, particularly endogenous lipid mediators,
such as resolvins and protectins [38], were not measured in
our model and could have contributed to the resolution of
the neutrophilic response, including effects on neutrophil
Figure 6. i.t. administration of rTRAIL induces neutrophil
apoptosis and reduces neutrophil numbers in vivo. TRAIL (5
g) was administered i.t. 24 h after nebulized administration
of 3 mg LPS; n  6 animals in each group. Total neutrophil
counts at 48 h from WT mice are shown as open bars
and from TRAIL-deficient mice as filled bars. There were sig-
nificantly more (A) cells and (B) neutrophils in the TRAIL-
deficient mice lavages when compared with WT, which signifi-
cantly reduced in response to TRAIL therapy. (C) At 48 h,
the percentage of apoptotic neutrophils was reduced in
TRAIL-deficient mice compared with WT mice but signifi-
cantly increased in response to TRAIL treatment. Histologic
sections of WT mice 24 h post-TRAIL treatment were TUNEL-
stained for detection of apoptotic events. (D) Numbers of
TUNEL-positive cells were significantly higher in WT (E
and F) mice following TRAIL treatment (tx). Neb, Nebulized.
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lifespan. Ingestion of apoptotic cells can also significantly
reprogram the cytokine network in infection-related pulmo-
nary models of inflammation [39], reducing key cytokines
involved in driving the polarization of classically activated
macrophages [40].
Importantly, we showed a significant reduction in neutrophil
apoptosis in the TRAIL-deficient mice at time-points coinci-
dent with inflammation resolution, demonstrating that re-
duced neutrophil apoptosis contributes to the increased neu-
trophil numbers detected in these mice. The rates of apoptosis
that we observed, although low, are comparable with those
that we have observed previously following i.t. LPS in caspase-
1-deficient mice, which have an intrinsic delay of neutrophil
apoptosis [1], in a murine model of acute Pseudomonas aerugi-
nosa pneumonia [35], and also are comparable with levels of
apoptosis in zebrafish models of neutrophilic inflammation
[41]. Other authors have also shown that small increases in
rates of neutrophil apoptosis, e.g., induced by the cyclin-de-
pendent kinase inhibitor Roscovitine [2], can substantially ac-
celerate inflammation resolution. Conversely, Bax inhibition
delays resolution, with similar relative changes in apoptosis to
those observed in this manuscript [42]. Very small, absolute
changes in apoptosis can have major differences for cell popu-
lations over time. For example, a 0.5% difference from 3.8%
to 3.3% of apoptotic CD4 T cells has been shown over time
to be associated with a very profound effect in immune recon-
stitution in HIV infection, resulting in alterations in mean
CD4 T cell counts from 249 to 632 cells/mL [43]. Early
modeling studies of CD4 T cell apoptosis within LNs showed
that a very small increase in percentage of apoptotic cells fol-
lowing antibody treatment, from 0.5% to 1%, was sufficient to
substantially reduce cell numbers [44]. Modeling data sug-
gested that each apoptotic cell was visible only for 50 min,
presumably prior to efferocytosis and degradation, so the tran-
sient nature of the “free” apoptotic population likely explains
why small numbers of apoptotic cells reflect substantial shifts
in population numbers [45].
We measured IgM, a recognized marker of a pulmonary vas-
cular leak in murine models of lung injury [24, 46] and also,
importantly, of ARDS in humans [47]. Changes in BAL levels
of IgM correlate well with changes in albumin and total pro-
tein in BAL [24, 46]. We observed a doubling of IgM levels in
TRAIL-deficient compared with WT mice at 48 h and 72 h
postinjury, a difference comparable with other studies [24, 48]
and demonstrating increased vascular permeability in TRAIL-
deficient compared with WT mice.
Histological analysis of murine lungs instilled with LPS re-
vealed up-regulation of TRAIL on the airway epithelium when
compared with mice instilled with saline. This epithelial ex-
pression of TRAIL could affect cell recruitment to the lung, as
work by Li et al. [49] showed that TRAIL induces the expres-
sion of E-selectin, ICAM-1, and IL-8, promoting adhesion of
leukocytes to the vascular endothelium. However, our data do
not suggest that this is a major contributor to the neutrophilic
inflammation and instead, raise the possibility that epithelial
TRAIL could down-regulate neutrophilic inflammation by in-
duction of apoptosis. Importantly, TUNEL staining of lung
sections did not suggest any excess of epithelial cell death as a
result of these cells expressing TRAIL. Macrophage expression
of death receptor ligands also plays a role in apoptosis induc-
tion. A role for macrophage FasL induction of target cell kill-
ing has been described for lymphocytes [50] and monocytes
[51]. TRAIL-mediated killing of lymphocytes is also described
Figure 7. i.p. administration of rTRAIL induces neutrophil apoptosis and re-
stores neutrophil numbers in vivo. TRAIL (5 g) was injected into the perito-
neal cavity 6 h after zymosan administration; n  6 animals in each group.
Total neutrophil counts from WT mice are shown as open bars and from
TRAIL-deficient mice, as filled bars. There were significantly more (A) cells
and (B) neutrophils in the TRAIL-deficient mice lavage when compared
with WT, which significantly reduced in response to TRAIL therapy. (C) At
24 h, the percentage of apoptotic neutrophils was reduced in TRAIL-defi-
cient mice compared with WT mice but significantly increased in response to
TRAIL treatment.
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[52]. However, we observed only infrequent TRAIL expression
by alveolar macrophages in this model over a range of time-
points, and again, this was not associated with any loss of mac-
rophage numbers. Recent data show that levels of soluble
TRAIL in BAL samples from ARDS patients are significantly
elevated and correlate with neutrophil numbers in the BAL
[53]. Neutrophils express TRAIL [54] and up-regulate it in
response to certain proinflammatory cytokines [55]. However,
histological data suggested that epithelial cells and to a lesser
extent, macrophages were the major source of TRAIL in our
model, and we were unable to detect BAL neutrophil expres-
sion of TRAIL by flow cytometry (data not shown).
We also investigated whether the persistent neutrophilic in-
flammation observed in TRAIL-deficient mice is restricted to
the lung or is a more widespread phenomenon. Zymosan-in-
duced peritonitis caused increased total neutrophil numbers
and reduced neutrophil apoptosis in TRAIL-deficient com-
pared with WT mice to a similar extent to the acute lung in-
jury model. Taken together, these data suggest that TRAIL
may play a physiological role in regulating the neutrophil lifes-
pan at sites of inflammation. Nonetheless, it should be noted
that neutrophilic inflammation still resolves in the absence of
TRAIL, in keeping with a role for other endogenous media-
tors, such as resolvins and related lipids [56] in physiologic
resolution, mediators that may potentially also compensate for
the absence of TRAIL in limiting the lifespan of inflammatory
neutrophils.
Treatment with exogenous TRAIL was evaluated in both
models of inflammation and resulted in increased levels of
neutrophil apoptosis and reduced neutrophil numbers, partic-
ularly in TRAIL-deficient but also significantly in WT mice.
These findings fit with previous studies using TRAIL-deficient
mice in models of listeriosis [17] and meningitis [18], which
provided evidence that TRAIL-deficient mice show prolonged
inflammation [18] and delayed neutrophil apoptosis [17],
which could be abrogated by TRAIL treatment. Yao et al. [57]
have also demonstrated that intra-articular injection of TRAIL
reduces leukocyte infiltration in a rabbit knee model of arthri-
tis. More recently, Weckmann et al. [58], in a murine model
of asthma, showed increased pulmonary epithelial expression
of TRAIL, as in our studies, but also, that inhibition of TRAIL
function attenuated allergic inflammation. In contrast, we have
shown that the absence of TRAIL is associated with enhanced
inflammation in the lung, as in other models of nonallergic
inflammation [18]. One theoretical advantage of TRAIL treat-
ment for neutrophilic inflammation is that it induces death in
a limited range of cell types [12]. We found no evidence of
increased loss of alveolar macrophages from BAL and no evi-
dence of excess epithelial cell death on TUNEL staining.
Moreover, although we did not directly assess NF-B activation
of BAL cells, there was no increase in BAL levels of NF-B-
dependent neutrophil chemokines following TRAIL treatment.
Our data therefore suggest TRAIL treatment may have bene-
ficial effects in acute lung injury by reducing the acute inflam-
matory response. In contrast, the FasL-Fas system appears to
have a predominantly proinflammatory effect, up-regulating
neutrophil chemokines [7] and inducing epithelial cell apo-
ptosis [59]. Indeed, intrapulmonary instillation of FasL is suffi-














Figure 8. TRAIL regulates inflammatory neutro-
phil apoptosis. A proposed model for TRAIL
regulating inflammation resolution by modula-
tion of neutrophil lifespan. In WT mice, TRAIL
expression by tissue cells, e.g., the respiratory
epithelium, can induce apoptosis of recruited
neutrophils. In TRAIL-deficient mice, inflamma-
tory cell survival is prolonged until engagement
of a constitutive program of neutrophil apopto-
sis. Exogenous TRAIL accelerates the apoptotic
death of neutrophils in TRAIL-deficient and WT
mice.
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In summary, we show that the absence of TRAIL results in en-
hancement of neutrophilic inflammation, suggesting that this
ligand may have a role in regulating physiologic inflammation. In
two robust and well-characterized models of inflammation, we
show that TRAIL treatment restores the phenotype in TRAIL-
deficient mice but importantly, also reduced neutrophilic inflam-
mation in WT mice. Recent data from Rossi et al. [2] have shown
that acceleration of neutrophil apoptosis can ameliorate inflam-
mation in multiple murine models and are supported by data
from other strategies for modulation of neutrophil apoptosis in
inflammation in vivo, e.g., via hypoxia signaling pathways [61].
The data presented similarly suggest a possible therapeutic role
for TRAIL that can be explored further in more injurious models
of persistent neutrophilic inflammation.
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